Botanix Pharmaceuticals Ltd
ASX:BOT
Intrinsic Value
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. [ Read More ]
The intrinsic value of one
BOT
stock under the Base Case scenario is
0.004
AUD.
Compared to the current market price of 0.28 AUD,
Botanix Pharmaceuticals Ltd
is
Overvalued by 99%.
BOT's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
BOT or that its price is influenced by factors unrelated to fundamentals.
Botanix Pharmaceuticals Ltd's market capitalization is 433.2m AUD.
BOT stock price is 0.28 AUD.
BOT stock (0.004 AUD) is 99% less than its price (0.28 AUD).
BOT. Open DCF Valuation
BOT stock (0.004 AUD) is 99% less than its price (0.28 AUD). Open Relative Valuation
BOT.
BOT's Revenue has grown by an exceptional 47% over the past 12 months.
BOT's ROE (Return on Equity) has significantly decreased in the last 3 years from -31% to -47%, and is approaching profitability.
BOT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -234% to -98%, and is approaching profitability.
BOT has negative Operating Income for the last twelve months.
BOT has negative Net Income for the last twelve months.
BOT's ROE (Return on Equity) for the past 12 months is negative and is equal to -47%.
BOT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -98%.
BOT's Revenue has been growing by an exceptional 56% per year for the last 3 years.
BOT has negative Free Cash Flow for the last twelve months.
BOT has very high three-year average ROIC (Return on Invested Capital): 49%. The company is very efficient at using invested capital to generate operating income.
BOT has negative three-year average ROE (Return on Equity): -53%. The company is not efficient at transforming stockholders' equity into net income.
BOT's short-term assets (22m AUD) exceed its short-term liabilties (2m AUD).
BOT's long-term assets (48m AUD) exceed its long-term liabilties (2m AUD).
BOT's D/E (Debt to Equity) is very low and is equal to 0.
BOT's Altman Z-Score is very high and is equal to 73.57.
BOT earns more than enough operating income (-18m AUD) to safely cover interest payments on its debt (-570 AUD).
Valuation Backtest
Botanix Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
BOT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Botanix Pharmaceuticals Ltd
Balance Sheet Decomposition
Botanix Pharmaceuticals Ltd
| Current Assets | 21.8m |
| Cash & Short-Term Investments | 18.3m |
| Receivables | 219.6k |
| Other Current Assets | 3.2m |
| Non-Current Assets | 25.9m |
| PP&E | 61.7k |
| Intangibles | 25.8m |
| Current Liabilities | 2.3m |
| Accounts Payable | 1.3m |
| Other Current Liabilities | 1m |
Earnings Waterfall
Botanix Pharmaceuticals Ltd
|
Revenue
|
588.4k
AUD
|
|
Operating Expenses
|
-18.9m
AUD
|
|
Operating Income
|
-18.3m
AUD
|
|
Other Expenses
|
3.7m
AUD
|
|
Net Income
|
-14.6m
AUD
|
Free Cash Flow Analysis
Botanix Pharmaceuticals Ltd
BOT Profitability Score
Profitability Due Diligence
Botanix Pharmaceuticals Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Botanix Pharmaceuticals Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
BOT Solvency Score
Solvency Due Diligence
Botanix Pharmaceuticals Ltd's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Score
Botanix Pharmaceuticals Ltd's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BOT Price Targets Summary
Botanix Pharmaceuticals Ltd
Shareholder Return
BOT Price
Botanix Pharmaceuticals Ltd
| Average Annual Return | -7.38% |
| Standard Deviation of Annual Returns | 44.11% |
| Max Drawdown | -91% |
| Market Capitalization | 417.7m AUD |
| Shares Outstanding | 1 575 139 968 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Botanix Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.
Contact
IPO
Employees
Officers
The intrinsic value of one
BOT
stock under the Base Case scenario is
0.004
AUD.
Compared to the current market price of 0.28 AUD,
Botanix Pharmaceuticals Ltd
is
Overvalued by 99%.
You don't have any saved screeners yet
